News
Asahi Kasei Life Science Expands BioOptimal™ Microfilter Lineup with New UMP and UJP
May 25, 2026
Asahi Kasei Life Science Corporation has expanded its BioOptimal™ microfilter lineup with the addition of the new BioOptimal UMP and BioOptimal UJP designed to support perfusion processes in upstream bioprocessing.
[May 25, 2026]
Asahi Kasei Life Science Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Yusuke Kanazawa) is pleased to announce the expansion of its BioOptimal microfilter lineup, designed for cell clarification in intensified upstream bioprocessing. As part of this expansion, BioOptimal UMP and BioOptimal UJP have been added to the BioOptimal product family alongside the existing BioOptimal MF-SL, broadening the cell retention device options available for perfusion clarification strategies.
BioOptimal UMP / MF-SL / UJP
As intensified upstream processing and perfusion continue to gain wider adoption in monoclonal antibody (mAb) manufacturing, biopharmaceutical manufacturers increasingly require cell-clarification solutions that deliver high product sieving, stable long-term operation, and reliable scalability from process development to GMP manufacturing. BioOptimal microfilters were developed to address these needs by leveraging Asahi Kasei’s hollow-fiber membrane technologies, including a range of pore sizes and materials, to enable efficient clarification while minimizing cell damage.
BioOptimal Product Highlights
New Products Added: BioOptimal UMP and BioOptimal UJP
BioOptimal UMP is a high-performance hollow-fiber microfilter specifically designed for TFF and rTFF applications in perfusion culture. It supports process intensification by providing exceptional antibody permeability (product sieving) and robust operational stability, helping to reduce harvest challenges such as membrane fouling. In an internal N perfusion evaluation conducted in TFF mode, BioOptimal UMP demonstrated greater than 90% product sieving for 32 days under high-density cell culture conditions.
BioOptimal UJP is designed for N-1 perfusion applications and provides stable, long-duration filtration even under high-flux conditions.
Looking Ahead
By expanding the BioOptimal lineup, Asahi Kasei Life Science will continue to support biopharmaceutical manufacturers in implementing process intensification strategies that enhance upstream productivity and operational robustness.
For More Information
[May 25, 2026]
Asahi Kasei Life Science Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Yusuke Kanazawa) is pleased to announce the expansion of its BioOptimal microfilter lineup, designed for cell clarification in intensified upstream bioprocessing. As part of this expansion, BioOptimal UMP and BioOptimal UJP have been added to the BioOptimal product family alongside the existing BioOptimal MF-SL, broadening the cell retention device options available for perfusion clarification strategies.
BioOptimal UMP / MF-SL / UJP
BioOptimal UMP / MF-SL / UJP
As intensified upstream processing and perfusion continue to gain wider adoption in monoclonal antibody (mAb) manufacturing, biopharmaceutical manufacturers increasingly require cell-clarification solutions that deliver high product sieving, stable long-term operation, and reliable scalability from process development to GMP manufacturing. BioOptimal microfilters were developed to address these needs by leveraging Asahi Kasei’s hollow-fiber membrane technologies, including a range of pore sizes and materials, to enable efficient clarification while minimizing cell damage.
BioOptimal Product Highlights
- High product sieving to support improved yields
- Reduced fouling and stable long-term operation
- Scalable performance from process development to manufacturing
New Products Added: BioOptimal UMP and BioOptimal UJP
BioOptimal UMP is a high-performance hollow-fiber microfilter specifically designed for TFF and rTFF applications in perfusion culture. It supports process intensification by providing exceptional antibody permeability (product sieving) and robust operational stability, helping to reduce harvest challenges such as membrane fouling. In an internal N perfusion evaluation conducted in TFF mode, BioOptimal UMP demonstrated greater than 90% product sieving for 32 days under high-density cell culture conditions.
BioOptimal UJP is designed for N-1 perfusion applications and provides stable, long-duration filtration even under high-flux conditions.
Looking Ahead
By expanding the BioOptimal lineup, Asahi Kasei Life Science will continue to support biopharmaceutical manufacturers in implementing process intensification strategies that enhance upstream productivity and operational robustness.
For More Information
